食管癌患者放疗前后血清癌胚抗原和细胞角蛋白19片段水平变化及临床意义被引量：7

Changes and clinical significance of serum carcinoembryonic antigen and cytokeratin fragment 19 in patients of esophageal cancer before and after radiotherapy

下载PDF

导出

摘要目的探讨联合检测食管癌患者放疗前后血清癌胚抗原(CEA)及细胞角蛋白19片段(CYFRA21-1)水平在疗效及倾后评价中的价值。方法用电化学发光法测定50例食管癌患者放射治疗前后血清中CEA和CYFRA21-1的水平,观察血清学指标改变与放疗疗效及预后的相关性。结果食管癌患者治疗后血清CEA及CYFRA21-1水平较治疗前显著降低(P<0.05);治疗后完全缓解和部分缓解的患者,其血清CEA和CYFRA21-1水平明显低于治疗后病情稳定甚至进展的患者(P<0.05)。结论联合检测血清CEA和CYFRA21-1水平对食管癌患者的放疗疗效及预后判断具有重要的参考价值。 Objective To investigate the curative effect and prognosis evaluation of measuring the levels of carcinoembryonic antigen（CEA） and cytokeratin fragment 19（CYFRA21-1） in patients of esophageal cancer before and after radiotherapy.Methods Serum CEA and CYFRA21-1levels were measured in 50 patients of esophageal cancer before and after radiotherapy by electricity chemiluminescence.Correlation between the change of serological parameters and the effect of prognosis was observed.Results Serum CEA and CYFRA21-1 levels of esophageal cancer patients were significantly lower after treatment than before treatment（P〈0.05）.Serum CEA and CYFRA21-1 levels in complete remission and partial remission patients were significantly lower than in stable or even progress patients after treatment（P〈0.05）.Conclusion The combination of serum CEA detection with CYFRA21-1 levels is an important reference value for esophageal cancer patients for their radiotherapy and prognosis.

作者杜兰宁邰霄辉王丽娜李淑萍

机构地区兰州大学第一医院放疗科甘肃省人民医院肿瘤内科

出处《兰州大学学报（医学版）》 CAS 2014年第2期63-65,共3页 Journal of Lanzhou University（Medical Sciences）

基金甘肃省胃肠重点实验室科研项目(GSWCKY-2012-009)

关键词食管癌癌胚抗原细胞角蛋白19片段三维适形精确放射治疗 esophageal cancer carcinoembryonic antigen cytokeratin fragment 19 3-dimensional conformal radiotherapy

分类号 R735.1 [医药卫生—肿瘤]

引文网络
相关文献

参考文献11

1KAWAGUCHI H, OHNO S, MIYAZAKI M, et al. CYFRA21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences[J]. Cancer, 2000, 89(7): 1413-1417.
2UENISHI T, YAMAZAKI O, TANAKA H, et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prog- nostic factor in intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2008, 15(2): 583-589.
3ARDIZZONI A, CAFFERATA M A, TISEO M, et al. Decline in serum carcinoembryonic antigen and cy- tokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with ad- vanced nonsmall cell lung cancer[J]. Cancer, 2006, 107(12): 2 842-2 849.
4MILLER i B, HOOGSTRATEN B, STAQUET M, et al. Reporting results of cancer treatment[J]. Can- cer, 1981, 47(1): 207-214.
5BROCKMANN J G, NOTTBERG H S, GLODNY B, et al. CYFRA 21-1 serum analysis in patients with esophageal cancer[J]. Clin Cancer Res, 2000, 6(11): 4 249-4 252.
6常鹏,陈江浩,王延,王辉,王岭.乳腺癌新辅助化疗前后血清免疫指标CA15-3、CA125和CEA水平的变化[J].细胞与分子免疫学杂志,2009,25(11):1032-1033. 被引量：12
7CARPELAN H M, LOUHIMO J, STENMAN U H, et al. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers[J]. Anticancer Res, 2002, 22(4): 2311-2316.
8KIJIMA H, OSHIBA G, KENMOCHI T, et al. Stromal CEA immunoreactivity is correlated with lymphatic invasion of human esophageal carcinoma[J]. Int J Oncol, 2000, 16(4): 677-682.
9MIDIRI G, AMANTI C, BENEDETT! M, et al. CEA tissue staining in colorectal cancer patients: a way to improve the usefulness of serial serum CEA eval- uation[J]. Cancer, 1985, 55(11): 2624-2629.
10LI Yan, LI Bao-sheng, WANG Zhong-tang, et al. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma[J]. Biomarkers, 2009, 14(7): 480-485.

二级参考文献15

1李小平,陈斌鸿,陈社安.血清CA153、CA125、CA199与CEA检测在乳腺癌诊断中的应用[J].广西医学,2004,26(7):975-977. 被引量：15
2王晨庄,王禾,张运涛,陈广生,汪涌.膀胱移行细胞癌组织肿瘤增殖核抗原Ki-67的表达意义[J].第四军医大学学报,2005,26(8):747-748. 被引量：6
3Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004 [J]. Ann Oncol, 2005, 16(3) : 481 -488.
4Daidone MG, Silvestrini R. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer [J].J Natl Cancer Inst Monogr, 2001, (30) : 27 -35.
5Jeruss JS, Mittendorf EA, Tucker SL, et al. Staging of breast cancer in the neoadjuvant setting[J]. Cancer Res, 2008, 68(16) : 6477 - 6481.
6Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value[J]. Clin Chem, 2006, 52(3) : 345 -351.
7Brooks M. Breast cancer screening and biomarkers[J]. Methods Mol Biol, 2009, (13)472:307-321.
8Arslan N, Serdar M, Deveci S, et al. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis [ J ]. Ann Nucl Med, 2000, 14(5) : 395 -399.
9Abbas A, Ali N, Hameed S, et al. Resectability rates in locally advanced esophageal carcinoma following neo-adjuvant chemoradiotherapy[J]. J Ayub Med Coll Abbottabad, 2003 ;15(4) :13 - 16.
10Wong J, Chang JH, Chang Q, et al. To observe the therapeutic effect of neoadjuvant chemotherapy and operation in Ⅲ stage esophago cardia carcinoma[J]. J Shandong Med,2005;45(6) :42 -43.